A Real‐World Phase IV Superiority Trial and Cost‐Effectiveness Analysis of the Addition of Low‐Dose Nivolumab to Triple Metronomic Chemotherapy Compared to the Paclitaxel Carboplatin Regimen in Recurrent or Metastatic Head and Neck Cancer Patients

A significant improvement in survival, tolerability, and reasonable cost-effectiveness was observed with low-dose immunotherapy when added to oral metronomic chemotherapy compared to conventional chemotherapy regimens.